iX Biopharma (SGX:42C) Asset Impairment Charge

: S$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

iX Biopharma's Asset Impairment Charge for the six months ended in Dec. 2023 was S$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.00 Mil.

iX Biopharma Asset Impairment Charge Historical Data

The historical data trend for iX Biopharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Asset Impairment Charge

iX Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Asset Impairment Charge																-	-	-	-	-

iX Biopharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.00 Mil.

iX Biopharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines